A new vaccine, detailed in Molecular Therapy, combines a chemical that mimics cocaine with an inactive common cold virus to produce a long lasting immunity to cocaine’s effects in mice.
This vaccine produces antibodies that specifically engulf cocaine molecules in the blood, preventing them from entering the brain to activate the reward centers (thereby selectively blocking cocaine’s effects).
The approach, developed by NIDA-funded researchers at Weill Cornell Medical College, has been called novel because it produces high levels of anti-cocaine antibodies that persistently reverse the behavioral effects of cocaine in mice.
It builds upon previous anti-cocaine vaccine work, offering promise for the medical treatment of addiction to cocaine as well as other drugs. Click to view the article by Hicks, et al. For more information, please contact the NIDA Press Office at (301) 443-6245 or email@example.com.